放疗联合替莫唑胺治疗老年高级别脑胶质瘤术后患者临床观察

Radiotherapy Combined with Temozolomide in the Treatment of Postoperative Patients with Highly Malignant Brain Glioma

目的 观察放疗联合替莫唑胺治疗老年高级别脑胶质瘤术后患者的远期疗效和安全性。方法 56例老年高级别脑胶质瘤术后患者分为2组。观察组29例采用调强放疗联合替莫唑胺治疗。对照组27例单纯采用调强放疗。比较2组的远期疗效和不良反应。结果 观察组疾病无进展生存时间为(18.48±5.12)个月,高于对照组的(12.93±3.93)个月,差异有统计学意义(t=4.53,P<0.05)。观察组总生存时间为(20.69±4.62)个月,对照组为(18.63±3.70)个月,差异无统计学意义(t=1.83,P>0.05)。2组恶心呕吐、骨髓抑制、放射性脑损伤发生率比较差异均无统计学意义(χ^2=2.18、1.82、0.60,P均>0.05)。结论 放疗联合替莫唑胺治疗老年高级别脑胶质瘤术后患者具有一定生存优势,且安全性良好。

Objective To observe the long-term efficacy and safety of radiotherapy combined with temozolomide in the treatment of postoperative patients with highly malignant brain glioma. Methods Fifty-six postoperative patients with highly malignant brain glioma were divided into two groups. Twenty-nine patients in the observation group received the intensity modulated radiotherapy combined with temozolomide, and 27 patients in the control group received the intensity modulated radiotherapy. The long-term efficacy and toxicities were compared between two groups. Results The disease progression-free survival time in the observation group was (18.48±5.12) months, and was (12.93±3.93) months in the control group ( t = 4.53, P <0.05). The disease progression-free survival time in the observation group was (20.69±4.62) months ,and was (18.63±3.70) months in the control group ( t = 1.83, P >0.05). There was no statistically significant differences in the nausea and vomiting, bone marrow suppression, radiation brain damage incidences between the two groups (χ^ 2=2.18,1.82,0.60;P >0.05). Conclusion Radiotherapy combined with temozolomide is safe and effect in the treatment of postoperative patients with highly malignant brain glioma.